[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL1965801T3 - Połączenie AZD2171 i premetreksedu - Google Patents

Połączenie AZD2171 i premetreksedu

Info

Publication number
PL1965801T3
PL1965801T3 PL06820574T PL06820574T PL1965801T3 PL 1965801 T3 PL1965801 T3 PL 1965801T3 PL 06820574 T PL06820574 T PL 06820574T PL 06820574 T PL06820574 T PL 06820574T PL 1965801 T3 PL1965801 T3 PL 1965801T3
Authority
PL
Poland
Prior art keywords
azd2171
pemetrexed
human
combination
antiangiogenic
Prior art date
Application number
PL06820574T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526132A external-priority patent/GB0526132D0/en
Priority claimed from GB0610708A external-priority patent/GB0610708D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1965801T3 publication Critical patent/PL1965801T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ink Jet (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06820574T 2005-12-22 2006-12-19 Połączenie AZD2171 i premetreksedu PL1965801T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0526132A GB0526132D0 (en) 2005-12-22 2005-12-22 Combination Therapy
GB0610708A GB0610708D0 (en) 2006-05-31 2006-05-31 Combination therapy
EP06820574A EP1965801B1 (en) 2005-12-22 2006-12-19 Combination of azd2171 and pemetrexed
PCT/GB2006/004768 WO2007071970A2 (en) 2005-12-22 2006-12-19 Combination of azd2171 and pemetrexed

Publications (1)

Publication Number Publication Date
PL1965801T3 true PL1965801T3 (pl) 2011-07-29

Family

ID=37964934

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06820574T PL1965801T3 (pl) 2005-12-22 2006-12-19 Połączenie AZD2171 i premetreksedu

Country Status (20)

Country Link
US (1) US20080306094A1 (pl)
EP (1) EP1965801B1 (pl)
JP (1) JP2009520787A (pl)
KR (1) KR20080077678A (pl)
AT (1) ATE502641T1 (pl)
AU (1) AU2006328201B2 (pl)
BR (1) BRPI0620118A2 (pl)
CA (1) CA2631676A1 (pl)
CY (1) CY1111482T1 (pl)
DE (1) DE602006020919D1 (pl)
DK (1) DK1965801T3 (pl)
HK (1) HK1123976A1 (pl)
HR (1) HRP20110365T1 (pl)
IL (1) IL191797A0 (pl)
NO (1) NO20082566L (pl)
NZ (1) NZ568812A (pl)
PL (1) PL1965801T3 (pl)
PT (1) PT1965801E (pl)
SI (1) SI1965801T1 (pl)
WO (1) WO2007071970A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
MX2007016497A (es) * 2005-07-06 2008-03-07 Astrazeneca Ab Terapia de combinacion para cancer con azd2171 y gemcitabina.
SI1971338T1 (sl) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija ZD6474 in pemetrekseda
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
CA2789895C (en) 2010-03-08 2019-04-09 Spectrum Pharmaceuticals, Inc. Thioxanthone-based autophagy inhibitor therapies to treat cancer
CA2994167A1 (en) * 2015-07-30 2017-02-02 Expression Pathology, Inc. Quantifying fr-a and gart proteins for optimal cancer therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518341A (ja) * 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
PL205557B1 (pl) * 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
MXPA06014021A (es) * 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
MX2007016497A (es) * 2005-07-06 2008-03-07 Astrazeneca Ab Terapia de combinacion para cancer con azd2171 y gemcitabina.
TW200730191A (en) * 2005-12-15 2007-08-16 Astrazeneca Ab Combinations
SI1971338T1 (sl) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija ZD6474 in pemetrekseda

Also Published As

Publication number Publication date
DE602006020919D1 (de) 2011-05-05
ATE502641T1 (de) 2011-04-15
US20080306094A1 (en) 2008-12-11
CY1111482T1 (el) 2015-08-05
PT1965801E (pt) 2011-05-25
DK1965801T3 (da) 2011-06-14
IL191797A0 (en) 2008-12-29
KR20080077678A (ko) 2008-08-25
AU2006328201A1 (en) 2007-06-28
EP1965801A2 (en) 2008-09-10
HK1123976A1 (en) 2009-07-03
WO2007071970A2 (en) 2007-06-28
AU2006328201B2 (en) 2010-08-19
JP2009520787A (ja) 2009-05-28
HRP20110365T1 (hr) 2011-06-30
NZ568812A (en) 2011-09-30
WO2007071970A3 (en) 2007-08-09
EP1965801B1 (en) 2011-03-23
NO20082566L (no) 2008-07-31
SI1965801T1 (sl) 2011-06-30
BRPI0620118A2 (pt) 2011-11-01
CA2631676A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
EP1971338B8 (en) Combination of zd6474 and pemetrexed
HK1123976A1 (en) Combination of azd2171 and pemetrexed azd2171
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
ZA200600188B (en) Combination therapy
IL177953A0 (en) Combination therapy including azd2171 and a taxane
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent